Clinical trial
A Multi-Center, Randomized, Double-Blind, Parallel Phase III Study to Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled
NCT03482180 is registered in ClinicalTrials.gov with Kuhnil Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-Center, Randomized, Double-Blind, Parallel Phase III Study to Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled
- Lead sponsor
- Kuhnil Pharmaceutical Co., Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- May 4, 2016
- Completion date
- March 23, 2018
- Enrollment
- 215 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.